...
首页> 外文期刊>Asian Pacific Journal of Cancer Prevention >Clinicopathological Features of Indonesian Breast Cancers with Different Molecular Subtypes
【24h】

Clinicopathological Features of Indonesian Breast Cancers with Different Molecular Subtypes

机译:不同分子亚型的印尼乳腺癌的临床病理特征

获取原文

摘要

Background: Breast cancer is a heterogeneous disease with molecular subtypes that have biological distinctness and different behavior. They are classified into luminal A, luminal B, Her-2 and triple negative/basal-like molecular subtypes. Most of breast cancers reported in Indonesia are already large size, with high grade or late stage but the clinicopathological features of different molecular subtypes are still unclear. They need to be better clarified to determine proper treatment and prognosis. Aim: To elaborate the clinicopathological features of molecular subtypes of breast cancers in Indonesian women. Materials and Methods: A retrospective cross-sectional study of 84 paraffin-embedded tissues of breast cancer samples from Dr. Sardjito General Hospital in Central Java,Indonesia was performed. Expression of ER, PR, Her-2 and Ki-67 was analyzed to classify molecular subtypes of breast cancer by immunohistochemistry. The relation of clinicopathological features of breast cancers with molecular subtypes of luminal A, luminal B, Her-2 and triple negative/basal-like were analyzed usingPearson`s Chi-Square test. A p-value of 50 years old women (p:0.028), low grade cancer (p:0.09), negative lymph node metastasis (p:0.034) and stage III (p:0.017). Eventhough the difference was insignificant, luminal A subtype breast cancer was mostly found in small size breast cancer (p:0.129). Her-2+ subtype breastcancer was more commonly diagnosed with large size, positive lymph node metastasis and poor grade. Triple negative/basal-like cancer was mostly diagnosed among <50 years old women. Conclusions: This study suggeststhat immunohistochemistry-based subtyping is essential to classify breast carcinoma into subtypes that vary in clinicopathological features, implying different therapeutic options and prognosis for each subtype.
机译:背景:乳腺癌是一种异质性疾病,其分子亚型具有生物学差异和不同行为。它们分为腔A,腔B,Her-2和三重负/基底样分子亚型。在印度尼西亚报道的大多数乳腺癌已经很大,具有高级别或晚期,但是不同分子亚型的临床病理特征仍不清楚。需要更好地阐明它们,以确定正确的治疗方法和预后。目的:详细阐述印度尼西亚妇女乳腺癌分子亚型的临床病理特征。材料与方法:对来自印度尼西亚中爪哇省Sardjito总医院的84个石蜡包埋的乳腺癌组织进行了回顾性横断面研究。通过免疫组织化学分析ER,PR,Her-2和Ki-67的表达以对乳腺癌的分子亚型进行分类。使用皮尔逊氏卡方检验分析了乳腺癌的临床病理特征与管腔A,管腔B,Her-2和三重阴性/基底样分子亚型的关系。 50岁女性(p:0.028),低度癌症(p:0.09),淋巴结转移阴性(p:0.034)和III期(p:0.017)的p值。尽管差异不明显,但在小尺寸乳腺癌中主要发现管腔A型亚型乳腺癌(p:0.129)。她的2+亚型乳腺癌更常被诊断为大尺寸,阳性淋巴结转移和较差的分级。三阴性/基底样癌多见于50岁以下的女性。结论:这项研究表明,基于免疫组织化学的亚型对于将乳腺癌分类为临床病理特征各异的亚型至关重要,这意味着每种亚型都有不同的治疗选择和预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号